))
Rivaroxaban beats aspirin for VTE
Manage episode 312707129 series 3242730
Content provided by MDedge. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MDedge or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended VTE compared with aspirin. Also today, bone biopsy diagnostics for osteomyelitis vary widely, variation in bacterial drug susceptibility are tied to the risk of TB relapse, and CTA cuts MIs in patients with stable chest pain.
100 episodes
Share
